LH · Labcorp Holdings

The thesis

Labcorp's third-quarter beat, its raised 2026 guidance and 11.5% Central Labs growth give the shares a modestly better than even chance of beating the S&P 500 over the next three months. The Centers for Medicare & Medicaid Services (CMS) test that view first with final 2027 lab payment rates, due in late November 2026. The company's 2027 outlook, expected in February 2027, settles it.

The rating is Medium because orders and guidance support the case while the price already sits at its high. On 10 November 2026, chief financial officer Julia Wang told the UBS Global Healthcare Conference that the Medicare rate reset is manageable, according to Investing.com's 11 November 2026 recap. She put the 2027 impact at about $125 million of revenue and adjusted operating income before mitigation, slightly less than 1% of company revenue. She also said 2027 margin expansion would be harder if the cuts take effect as designed.

The shares closed at $372.32 on 12 November 2026 and touched an intraday 52-week high of $375.10 that day. They are up 17.3% over three months. The price already reflects most of the post-report optimism: the 12 November 2026 close is within 2% of Barclays' $380 target and above Deutsche Bank's $355, both set on 29 October 2026.

Bullish and bearish views on Labcorp Holdings Inc.

The bull case on Labcorp Holdings Inc. (LH), in brief: Central lab growth is accelerating. The bear case: Medicare fee cuts arrive in 2027.

Bull case

• Central lab growth is accelerating. Biopharma Laboratory Services revenue was $866.7 million in the third quarter, up 8.5%, or 9.6% organic, and Central Labs grew 11.5%, according to the company's 28 October 2026 8-K. On 10 November 2026 Wang said quarterly book-to-bill was 1.13 and the 2026 central lab outlook is now high single-digit organic growth, per Investing.com.
• Orders keep running ahead of revenue. The trailing twelve-month book-to-bill ratio was 1.10 on $3.59 billion of net orders as of 30 September 2026. Backlog was $8.92 billion, up 3.9% from a year earlier.
• Results beat and guidance rose. Third-quarter revenue was $3.81 billion, up 6.9% from $3.56 billion a year earlier, per the 10-Q filed 30 October 2026. Adjusted earnings per share (EPS) was $4.78, up 14.5%, and 2026 adjusted EPS guidance rose to $18.30–$18.70 from $18.10–$18.55 on 28 October 2026.
• Management is adding cost offsets. Wang said on 10 November 2026 that the annual savings target for the LaunchPad cost program rises to $125–150 million from 2027, up from $100–125 million, according to Investing.com. She kept the target of 75–150 basis points of margin expansion by the end of 2029.
• Medicare cuts have a yearly ceiling. The CMS fact sheet on preliminary rates, released 21 September 2026, says a test's payment cannot fall more than 15% in a year from 2027 through 2029. Chief Healthcare Executive reported on 4 November 2026 that the final 2027 physician fee schedule rule keeps that cap.
• Several targets sit above the price. UBS raised its target to $420 and Truist to $395 on 29 October 2026, Mizuho went to $400 from $355 on 4 November 2026, and Seeking Alpha reported HSBC's upgrade to Buy with a $410 target on 5 November 2026.

Bear case

• Medicare fee cuts arrive in 2027. Becker's Hospital Review reported the preliminary 2027 rates average about 16% below 2026 rates. The Healthcare Financial Management Association reported on 22 September 2026 that 1,171 codes had lower calculated rates and CMS projects about $1 billion a year in Medicare savings. Final rates had not been published as of 12 November 2026.
• 2027 margin growth is at risk. Wang said on 10 November 2026 that margin expansion in 2027 would be harder if the rate cuts are implemented as designed, according to Investing.com.
• Reported profit grew much more slowly. Third-quarter GAAP diluted EPS was $3.22, up 3.3%, while adjusted EPS grew 14.5%, according to the 28 October 2026 8-K.
• Early-stage drug services are flat. Early Development revenue grew 0.4% in the third quarter, so biopharma momentum depends on Central Labs.
• Free cash flow guidance did not move. On 28 October 2026 the company raised EPS guidance but left its 2026 free cash flow range at $1,240–$1,360 million.
• Insiders keep selling into strength. A Form 4 filed 12 November 2026 shows Brian Caveney, president of Biopharma Laboratory Services, sold 2,000 shares at $372.04 on 10 November 2026. Earlier Form 4 filings show director Richelle Parham sold 1,078 shares at $361.22 on 30 October 2026 and Diagnostics president Bryan Vaughn sold 306 shares at $353.70 on 3 November 2026 under a Rule 10b5-1 plan.

Price setup

The shares closed at $372.32 on 12 November 2026, after an intraday 52-week high of $375.10 the same session. The 52-week closing low was $250.39 on 12 January 2026. The three-month gain is 17.3%.

In adjusted daily closes as of 12 November 2026, the 50-day moving average is $328.86 and the 200-day moving average is $291.10. The price is about 13% above the 50-day average, a gap built mostly in the sessions after the 28 October 2026 report. The shares have held between $363.30 (close on 5 November 2026) and $372.32 over the last six sessions.

The level the case turns on is Barclays' pre-report target of $330, which now sits next to the 50-day average. A close back there would erase most of the gain since the third-quarter report. On the upside, the price is approaching the cluster of post-report targets between Barclays' $380 and Morgan Stanley's $388, both set 29 October 2026.

Catalysts ahead

• 24 November 2026: Record date for the $0.72 quarterly dividend, payable 11 December 2026. A routine capital-return event that confirms the dividend is steady. It does not test the growth case.
• ~30 November 2026 (est.): CMS publication of final 2027 Medicare clinical lab fee schedule rates, scheduled for November 2026 with no day named. It shows whether the company's estimate of about $125 million for the 2027 impact still stands, or whether final rates come in deeper than the preliminary ones.
• ~12 January 2027 (est.): J.P. Morgan Healthcare Conference presentation. Management may show how much of the Medicare impact central lab growth, cost savings and acquisitions can absorb.
• ~17 February 2027 (est.): Fourth-quarter 2026 report and 2027 guidance. The company said it will give 2027 guidance in February 2027, including the Medicare effect. Guidance below the 2026 EPS range would break the case.

What would change the view

A daily close below $330, Barclays' price target before the third-quarter report, which would erase most of the post-report gain. 2027 adjusted EPS guidance in February 2027 below the 2026 range of $18.30–$18.70 would also break the case.

The risks this note tracks, each with what would confirm it:

• Final Medicare lab fee schedule cuts for 2027 come in deeper than the preliminary rates. Confirmed by: a final CMS fee schedule, or company commentary, that raises the 2027 impact above the roughly $125 million estimated on 28 October 2026 and repeated on 10 November 2026.
• Pharma clients slow trial spending and Central Labs growth fades. Confirmed by: Biopharma book-to-bill below 1.0, or Central Labs growth falling to low single digits, in the fourth-quarter 2026 report.
• Medicare cuts stall margin expansion in 2027. Confirmed by: February 2027 guidance showing flat or lower adjusted operating margin for 2027, or a cut to the 75–150 basis point margin target for 2029.
• Acquisitions add revenue but dilute margins or cash flow. Confirmed by: a cut to the $1,240–$1,360 million 2026 free cash flow range, or 2027 guidance showing lower adjusted margins as acquired labs are absorbed.
• Insiders keep selling as the shares reach analyst targets. Confirmed by: further open-market sales by executives in SEC Form 4 filings after 12 November 2026, or target cuts to below the price by brokers such as Barclays or Deutsche Bank.

What it trades with

Labcorp trades with US clinical lab operators such as Quest Diagnostics, which share the same Medicare rate exposure. The CMS final rate release is a sector-wide event and is likely to move those peers on the same day. The Central Labs business ties the shares to pharmaceutical trial spending and the contract research cycle. Labcorp's largely domestic, Medicare- and insurer-linked testing revenue has little connection to the AI and semiconductor stocks that drive much of the broader index.